Objectives:To discuss the mechanism of Sheng Yang San Huo decoction on diabetic peripheral neuropathy using the network pharmacology method.Methods:The BATMAN-TCM database,TCM-ID database,Chinese Natural Product Chemi...Objectives:To discuss the mechanism of Sheng Yang San Huo decoction on diabetic peripheral neuropathy using the network pharmacology method.Methods:The BATMAN-TCM database,TCM-ID database,Chinese Natural Product Chemical Composition Database,and TCMIP database were employed to screen the chemical active ingredients of each herb in Sheng Yang San Huo decoction based on the“Libinsky Drug Rules”.SwissTargetPrediction was used to screen effective action targets for each herb in the prescription.Additionally,Cytoscape 3.7.0 was utilized to construct a“drug-target”network.GeneCards,OMIM,and MaLaCards databases were utilized to gather targets related to diabetic peripheral neuropathy.VENNY 2.1 online platform was employed to match drug and disease targets,draw a Venn diagram,and construct a“drug-active compounds-common target”network using Cytoscape 3.7.0.gene ontology biological process analysis and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis for the targets were conducted using the DAVID 6.8 database.Enrichment analysis results were visualized using the OmicShareTool online platform.Molecular docking was performed using CB-Dock2.Results:Following screening,a total of 217 active compounds and 132 potential targets were identified in Sheng Yang San Huo decoction.The effects are primarily enriched in pathways such as Lipid and Atherosclerosis,AGE-RAGE signaling pathway in diabetic complications,and the IL-17 signaling pathway.The binding energy of the key active ingredients to the core protein targets of DPN was favorable.Conclusion:The study reveals the characteristics of multiple targets and pathways of Sheng Yang San Huo decoction,providing new insights for the clinical application of this prescription.展开更多
AIM: To explore the effect of Sinai san decoction on the development of non-alcoholic steatohepatitis induced by CCL4 combined with a fat-rich diet in rats.METHODS: Twenty-seven Sprague-Dawley rats were divided into t...AIM: To explore the effect of Sinai san decoction on the development of non-alcoholic steatohepatitis induced by CCL4 combined with a fat-rich diet in rats.METHODS: Twenty-seven Sprague-Dawley rats were divided into three groups randomly: control group (n = 9),model group (n = 9) and treatment group (n = 9). The rats of model group and treatment group were given small dosage of CCL4 combined with a fat-rich diet, andthose of control group were given normal diet. After four weeks of fat-rich diet feeding, the rats of treatment group were given Sinai san decoction. The serum levels of aminotransferase and lipid were measured, and the pathology of livers was observed by HE staining after the rats were sacrificed at eight weeks.RESULTS: The rats' livers presented the pathology of steatosis and inflammation with higher serum levels of ALT and AST in the model group. In the treatment group the serum ALT and AST levels decreased significantly and were close to the control group. The hepatic inflammation scores also decreased markedly, but were still higher than those of control group. And the degree of hepatocyte steatosis was similar to that of model group.CONCLUSION: Sinai san decoction may ameliorate the hepatic inflammation of rats with steatohepatitis induced by small dosage of CCL4 combined with a fat-rich diet,but does not prevent the development of hepatocyte steatosis.展开更多
Objective：San＇ao Decoction（三拗汤,SAD）,as a representative Chinese medicine（CM）formula, was chosen to evaluate the effect of airway inflammation and hyperresponsiveness on the lipopolysaccharide （LPS）enhanced ...Objective：San＇ao Decoction（三拗汤,SAD）,as a representative Chinese medicine（CM）formula, was chosen to evaluate the effect of airway inflammation and hyperresponsiveness on the lipopolysaccharide （LPS）enhanced asthma model.Methods：The asthma model was reproduced in the Balb/C mice sensitized by ovalbumin（OVA）,challenged by OVA and LPS.After Balb/C mice＇s administration of a dose（0.0024 g/kg）of dexamethasone acetate,and three doses（2.2 g/kg,4.4 g/kg and 8.8 g/kg）of SAD,airway inflammation and responsiveness were observed.The airway inflammation was detected by counting bronchoalveolar lavage fluid （BALF）cells and lung histopathology.Also,differential expressions of interferon-r（IFN-γ）,interleukin-4（IL-4）, and IL-5 in the supernatants of BALF were examined.The changes in airway responsiveness indicated by lung resistance（R_L）and stimulated by acetylcholine（Ach）were determined.Results：Small-dose SAD hardly inhibit airway inflammation or hyperresponsiveness in the LPS-enhanced asthma,while medium-dose and high-dose SAD significantly inhibited the airway hyperresponsiveness,and to some extent,reduced airway inflammation. Meanwhile,the small-dose,medium-dose,and high-dose SAD promoted Th1-type cytokines（IFN-γ）and reduced Th2-type cytokines（IL-4,IL-5）to different extents,which led to a Th1/Th2 balance.Conclusion：SAD has a good therapeutic effect on airway hyperresponsiveness in the LPS-enhanced asthma model,but its definite influence on airway inflammation is not remarkable.展开更多
目的:观察针刺董氏奇穴联合内服中药治疗混合性焦虑抑郁障碍(Mixed Anxiety and Depressive Disorder,MADD)痰气郁结证的疗效。方法:选择2020年4月至2021年10月江海区中西医结合医院治疗的MADD患者90例,随机分为对照组、观察A组、观察B...目的:观察针刺董氏奇穴联合内服中药治疗混合性焦虑抑郁障碍(Mixed Anxiety and Depressive Disorder,MADD)痰气郁结证的疗效。方法:选择2020年4月至2021年10月江海区中西医结合医院治疗的MADD患者90例,随机分为对照组、观察A组、观察B组各30例。对照组予口服氟哌噻吨美利曲辛片,观察A组予内服温胆汤合丹栀逍遥散加减,观察B组在观察A组治疗的基础上予针刺董氏奇穴,均治疗12周,治疗后对比三组患者的医院焦虑抑郁量表(Hospital Anxiety and Depression Scale,HADS)评分、中医证候评分、临床疗效及不良反应。结果:治疗前,三组患者的HADS评分、痰气郁结证评分对比,差异无统计学意义(P>0.05);治疗后,三组患者的HADS评分、痰气郁结证评分均较治疗前下降(P<0.05),其中观察A组、观察B组的HADS评分、痰气郁结证评分均明显低于对照组(P<0.05),观察B组的HADS评分、痰气郁结证评分均明显低于观察A组(P<0.05)。观察B组的总有效率(93.33%)高于观察A组(86.67%)、对照组(73.33%)(P<0.05)。治疗期间,对照组不良反应发生率为13.33%,观察A组为6.67%,观察B组为10.00%,差异无统计学意义(P>0.05)。结论:针刺董氏奇穴联合内服中药具有行气开郁、化痰散结、清肝泻火之功效,治疗MADD痰气郁结证安全有效,值得在临床中推广应用。展开更多
基金the 2022 Chongqing Natural Science Foundation(Postdoctoral Project)(CSTB2022NSCQ-BHX0690)the 2022 Chongqing Postdoctoral Innovation Talent Support Plan(CQBX202212)the 2023 Chongqing Science and Health Joint Medical Research Project(2023QNXM002).
文摘Objectives:To discuss the mechanism of Sheng Yang San Huo decoction on diabetic peripheral neuropathy using the network pharmacology method.Methods:The BATMAN-TCM database,TCM-ID database,Chinese Natural Product Chemical Composition Database,and TCMIP database were employed to screen the chemical active ingredients of each herb in Sheng Yang San Huo decoction based on the“Libinsky Drug Rules”.SwissTargetPrediction was used to screen effective action targets for each herb in the prescription.Additionally,Cytoscape 3.7.0 was utilized to construct a“drug-target”network.GeneCards,OMIM,and MaLaCards databases were utilized to gather targets related to diabetic peripheral neuropathy.VENNY 2.1 online platform was employed to match drug and disease targets,draw a Venn diagram,and construct a“drug-active compounds-common target”network using Cytoscape 3.7.0.gene ontology biological process analysis and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis for the targets were conducted using the DAVID 6.8 database.Enrichment analysis results were visualized using the OmicShareTool online platform.Molecular docking was performed using CB-Dock2.Results:Following screening,a total of 217 active compounds and 132 potential targets were identified in Sheng Yang San Huo decoction.The effects are primarily enriched in pathways such as Lipid and Atherosclerosis,AGE-RAGE signaling pathway in diabetic complications,and the IL-17 signaling pathway.The binding energy of the key active ingredients to the core protein targets of DPN was favorable.Conclusion:The study reveals the characteristics of multiple targets and pathways of Sheng Yang San Huo decoction,providing new insights for the clinical application of this prescription.
文摘AIM: To explore the effect of Sinai san decoction on the development of non-alcoholic steatohepatitis induced by CCL4 combined with a fat-rich diet in rats.METHODS: Twenty-seven Sprague-Dawley rats were divided into three groups randomly: control group (n = 9),model group (n = 9) and treatment group (n = 9). The rats of model group and treatment group were given small dosage of CCL4 combined with a fat-rich diet, andthose of control group were given normal diet. After four weeks of fat-rich diet feeding, the rats of treatment group were given Sinai san decoction. The serum levels of aminotransferase and lipid were measured, and the pathology of livers was observed by HE staining after the rats were sacrificed at eight weeks.RESULTS: The rats' livers presented the pathology of steatosis and inflammation with higher serum levels of ALT and AST in the model group. In the treatment group the serum ALT and AST levels decreased significantly and were close to the control group. The hepatic inflammation scores also decreased markedly, but were still higher than those of control group. And the degree of hepatocyte steatosis was similar to that of model group.CONCLUSION: Sinai san decoction may ameliorate the hepatic inflammation of rats with steatohepatitis induced by small dosage of CCL4 combined with a fat-rich diet,but does not prevent the development of hepatocyte steatosis.
基金Supported by a Grant-in-aid for Scientific Research in the 11th Five-Year Plan,the Ministry of Science and Technology of P.R. China(No.2006BAI06A02-01)Natural Science Foundation of China(No.81072748)
文摘Objective：San＇ao Decoction（三拗汤,SAD）,as a representative Chinese medicine（CM）formula, was chosen to evaluate the effect of airway inflammation and hyperresponsiveness on the lipopolysaccharide （LPS）enhanced asthma model.Methods：The asthma model was reproduced in the Balb/C mice sensitized by ovalbumin（OVA）,challenged by OVA and LPS.After Balb/C mice＇s administration of a dose（0.0024 g/kg）of dexamethasone acetate,and three doses（2.2 g/kg,4.4 g/kg and 8.8 g/kg）of SAD,airway inflammation and responsiveness were observed.The airway inflammation was detected by counting bronchoalveolar lavage fluid （BALF）cells and lung histopathology.Also,differential expressions of interferon-r（IFN-γ）,interleukin-4（IL-4）, and IL-5 in the supernatants of BALF were examined.The changes in airway responsiveness indicated by lung resistance（R_L）and stimulated by acetylcholine（Ach）were determined.Results：Small-dose SAD hardly inhibit airway inflammation or hyperresponsiveness in the LPS-enhanced asthma,while medium-dose and high-dose SAD significantly inhibited the airway hyperresponsiveness,and to some extent,reduced airway inflammation. Meanwhile,the small-dose,medium-dose,and high-dose SAD promoted Th1-type cytokines（IFN-γ）and reduced Th2-type cytokines（IL-4,IL-5）to different extents,which led to a Th1/Th2 balance.Conclusion：SAD has a good therapeutic effect on airway hyperresponsiveness in the LPS-enhanced asthma model,but its definite influence on airway inflammation is not remarkable.
文摘目的:观察针刺董氏奇穴联合内服中药治疗混合性焦虑抑郁障碍(Mixed Anxiety and Depressive Disorder,MADD)痰气郁结证的疗效。方法:选择2020年4月至2021年10月江海区中西医结合医院治疗的MADD患者90例,随机分为对照组、观察A组、观察B组各30例。对照组予口服氟哌噻吨美利曲辛片,观察A组予内服温胆汤合丹栀逍遥散加减,观察B组在观察A组治疗的基础上予针刺董氏奇穴,均治疗12周,治疗后对比三组患者的医院焦虑抑郁量表(Hospital Anxiety and Depression Scale,HADS)评分、中医证候评分、临床疗效及不良反应。结果:治疗前,三组患者的HADS评分、痰气郁结证评分对比,差异无统计学意义(P>0.05);治疗后,三组患者的HADS评分、痰气郁结证评分均较治疗前下降(P<0.05),其中观察A组、观察B组的HADS评分、痰气郁结证评分均明显低于对照组(P<0.05),观察B组的HADS评分、痰气郁结证评分均明显低于观察A组(P<0.05)。观察B组的总有效率(93.33%)高于观察A组(86.67%)、对照组(73.33%)(P<0.05)。治疗期间,对照组不良反应发生率为13.33%,观察A组为6.67%,观察B组为10.00%,差异无统计学意义(P>0.05)。结论:针刺董氏奇穴联合内服中药具有行气开郁、化痰散结、清肝泻火之功效,治疗MADD痰气郁结证安全有效,值得在临床中推广应用。
